dromlakhani Consider OC‑antiandrogen combination for severe hirsutism with distress or prior OC failure; avoid as first‑line
STEP 1 — Gather Information
Collect hirsutism severity (Ferriman‑Gallwey score), presence of emotional distress or psychosocial impact, duration and response to prior OC monotherapy, menstrual status, need for contraception, obesity, age ≥39 years, and baseline liver/kidney function.
Action: Proceed to Step 2 if patient has severe hirsutism with distress or has used an OC for ≥6 months with insufficient improvement.
STEP 2 — Rule In / Rule Out
Rule in: Severe hirsutism (FG ≥ 15) causing emotional distress or patient‑important hirsutism persisting despite ≥6 months of OC monotherapy.
Rule out: Mild hirsutism (FG < 8) without distress, OC‑naïve patients, pregnancy, active liver disease, or unaddressed VTE risk without low‑dose OC plan.
Action: If ruled in, advance to Step 3; otherwise consider OC monotherapy or direct hair removal methods.
STEP 3 — Classify or Stratify
Stratify by VTE risk: low risk (non‑obese, age < 39) vs high risk (obese or age ≥ 39). Ensure antiandrogen is paired with reliable contraception due to teratogenic potential.
Action: For low‑risk patients, choose any OC (EE 20‑35 µg) plus antiandrogen (e.g., spironolactone 100‑200 mg/day). For high‑risk patients, select OC with lowest effective EE dose (usually 20 µg) and low‑risk progestin (see Table 2) plus antiandrogen.
STEP 4 — Decide
Prescribe the selected OC‑antiandrogen combination, counsel on mandatory effective contraception, baseline labs (LFTs, K+, BP), and schedule follow‑up evaluation at 6 months to assess hirsutism improvement and side effects.
Action: Initiate therapy and arrange reassessment.
Clinical Guardrails / Mimics / Pitfalls
Do not use OC‑antiandrogen as first‑line for mild hirsutism or without distress. Always confirm effective contraception because antiandrogens are teratogenic. Avoid in pregnancy, active liver disease, or uncontrolled hyperkalemia (when using spironolactone). Monitor VTE risk, especially with OC; use lowest EE dose in high‑risk women. Do not combine multiple antiandrogens without evidence. Beware of drug interactions (e.g., spironolactone with ACE inhibitors/ARBs → hyperkalemia).
Concrete Clinical Example
A 28‑year‑old woman with PCOS presents with FG score 18, reports severe facial hair causing social avoidance and distress. She tried OC monotherapy (EE 30 µg + levonorgestrel) for 8 months with minimal improvement. She is non‑obese, no VTE risk factors, desires contraception. Action: Switch to OC containing EE 20 µg + norethindrone 0.5 mg plus spironolactone 100 mg BID. Counsel on need for reliable contraception and schedule follow‑up in 6 months.
Source: Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-00241